Fig. 3.

Baseline serum levels of adiponectin and morality at 3-year follow-up. a Serum levels of adiponectin in survival and non-survival. b Multivariate analyses for mortality according to adiponectin quartiles. Adjustments for age, obese (yes vs. no), previous CVD events (yes vs. no), NHISS, stroke syndrome (TACS vs. other), stroke subtype (Cardioembolic vs. other), acute treatment (no vs. yes), serum levels of glucose, CRP, eGFR, copeptin and NT-ProBNP. c ROC curves were utilized to evaluate the accuracy of serum level of adiponectin to predict mortality. d The Kaplan–Meier estimates of mortality stratified by baseline adiponectin quartiles. Adiponectin quartiles were defined as Q1 < 4.8 μg/mL, Q2 4.8–7.1 μg/mL, Q3 7.2–9.8 μg/mL and Q4 > 9.8 μg/mL. MACCE was defined as CVD death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization by percutaneous coronary intervention or coronary artery bypass grafting. Abbreviation see the Fig. 2